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Properdin Levels in Individuals with Chemotherapy-
Induced Neutropenia
Artsiom Tsyrkunou,1 Sarika Agarwal,1 Bibek Koirala,1 Robert W. Finberg,1 Rajneesh Nath,1 Bruce Barton,2 Stuart M. Levitz,1,a  
Jennifer P. Wang,1,a and Sanjay Ram1,a
Departments of 1Medicine and 2Quantitative Health Sciences, University of Massachusetts Medical School, Worcester
Background. Neutrophils produce and carry key components of the alternative pathway (AP) of complement, including proper-
din (P). The effect of chemotherapy-induced absolute neutropenia on circulating P levels and AP function has not been previously 
established.
Methods. We prospectively measured free P levels in serum from 27 individuals expected to develop neutropenia after adminis-
tration of chemotherapy for hematological malignancies in preparation for hematopoietic stem cell transplantation and here describe 
the relationship between serum P levels and the neutrophil count over time.
Results. When the absolute neutrophil count (ANC) was >500 cells/mm3 pre-chemotherapy, P levels were significantly higher 
than P levels associated with an ANC ≤500 cells/mm3 (median values 8392  ng/mL and 6355  ng/mL, respectively; P = .001). 
Pairwise comparison between pre-chemotherapy P levels and P levels at initial or last documented neutropenia before recovery 
showed a significant decline (P < .0001). No correlation was observed between P levels during neutropenia and after recovery 
of neutropenia in 20 subjects for which postneutropenia samples were obtained. A small but significant (P = .02) decrease in AP 
hemolytic activity was noted between baseline (preneutropenia) and samples obtained at the onset of neutropenia, but only with low 
(6.25%) and not higher (12.5 or 25%) serum concentrations.
Conclusions. A decline in P levels and AP activity could contribute to the increased risk of infection in neutropenic patients and 
warrants further study.
Keywords. human; neutropenia; properdin.
The complement system consists of over 30 fluid-phase pro-
teins and enzymes and several membrane-associated mole-
cules, which together regulate the innate immune response of 
the host to infections [1]. The classic and lectin complement 
pathways are initiated by binding of “recognition molecules” 
to the microbial surface, which include antibody or specific 
lectins (eg, mannan-binding lectin or ficolins), respectively. 
The alternative pathway (AP) of complement can be acti-
vated in 2 ways. In the conventional model (the C3 “tickover” 
model), complement C3 is spontaneously hydrolyzed and 
deposited on foreign surfaces; C3b deposition is then ampli-
fied by the positive feedback loop of the AP [2, 3]. A second 
model of AP activation is the properdin (P)-directed model, 
which involves recognition of activator surfaces by P, which 
then binds to C3b and forms a platform for AP C3 conver-
tase assembly [4]. This second model is consistent with that 
proposed by Pillemer et al [5] over 60 years ago. Properdin 
is the only known positive regulator of the complement sys-
tem and serves to stabilize the C3bBb complex, also known 
as AP C3 convertase [4]. Properdin is produced by neutro-
phils and stored in their secondary granules. Other cells that 
synthesize P include macrophages, monocytes, T cells, and 
endothelial cells [6–12]. A small amount of free P is present 
in human plasma at concentrations ranging from 4 to 25 µg/
mL [13–15]. Activation of neutrophils stimulates the release 
of P from secondary granules and augments complement 
activation on the proximate offending target [16].
Chemotherapy-induced neutropenia renders the host 
at increased risk for infections; the incidence of infections 
increases dramatically when absolute neutrophil counts (ANCs) 
drop below 500 cells/mm3 [17]. Low levels of P in this setting 
could decrease AP activation on microbial surfaces and con-
tribute to the increased risk of invasive infections. In addition, 
critically ill patients with sepsis have decreased amounts of P 
compared with age- and sex-matched controls [18]. We aimed 
to define the relationship between free P levels in serum and the 
absolute level of neutrophils in individuals who become neutro-
penic after receiving cytotoxic chemotherapy for hematological 
malignancy.
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MATERIALS AND METHODS
Study Population
Informed written consent was obtained from all donors before 
enrollment into the study. The University of Massachusetts 
Medical School Institutional Review Board committee approved 
the research protocol, and the study was performed in accord-
ance with the Declaration of Helsinki.
Subjects ≥18  years of age who were scheduled for elective 
chemotherapy before receiving hematopoietic stem cell trans-
plantation (HSCT) or cord blood transplantation were pro-
spectively recruited at the inpatient bone marrow unit at the 
University of Massachusetts Medical Center (Worcester, MA) 
from May 1, 2013 to January 31, 2014 (n = 31). The first 
blood sample was obtained before initiation of chemother-
apy and within 24 hours of the patient’s hospitalization (Day 
0). Subsequent blood samples (not more frequently than once 
every 48 hours) were obtained along with blood draws for rou-
tine care when the subjects became severely neutropenic with an 
ANC ≤500 cells/mm3. When possible, a final blood sample was 
obtained shortly after the patient recovered from severe neutro-
penia (ANC >500 cells/mm3). Individuals who received fresh 
frozen plasma were excluded from the study because this would 
affect P levels. To be eligible for analysis, each subject had to 
have a minimum of 2 blood samples in addition to the baseline 
sample. Of the 31 persons who agreed to participate in the study, 
1 was excluded because the neutrophil level was <500 cells/mm3 
at baseline and neutrophil counts did not recover during the 
course of hospitalization, and 3 were excluded because only 2 
blood samples were available; thus, 27 persons were included in 
the final analyses.
Sample Collection
Blood samples were collected and processed within 1 h of sam-
pling. Serum was separated from whole blood and stored at 
−80°C until the end of the recruitment process.
Quantification of Serum P Levels
Properdin was quantified by enzyme-linked immunosorbent 
assay using monoclonal anti-P antibody (Quidel, San Diego, 
CA) as the capture antibody to coat microtiter wells at a con-
centration of 0.5 µg/mL in phosphate-buffered saline (PBS) for 
3 hours at 37°C, followed by 15 hours at 4°C. Microtiter wells 
were washed thrice with PBS-0.05% Tween 20. Serum samples 
were diluted 1:250 and 1:500 in PBS-0.05% Tween 20. Dilutions 
of purified P (Complement Technology, Inc., Tyler, TX) were 
used to generate a standard curve. Commercially available sera 
from 3 normal adults and P-depleted serum (Complement 
Technology, Inc.) were used as controls. Immunoglobulin G 
purified from polyclonal goat antihuman factor P (Complement 
Technology, Inc.) over protein G sepharose (Sigma-Aldrich, St. 
Louis, MO) was biotinylated and used as the detecting anti-
body at a 1:1000 dilution in PBS-0.05% Tween 20. Bound P was 
detected with avidin alkaline phosphatase (Sigma-Aldrich) as 
substrate. Absorbance was set at 405 nm in a microtiter plate 
spectrophotometer.
Alternative Pathway Hemolytic Assay
Functional AP complement activation was performed on paired 
serum samples, 1 obtained at baseline and 1 on the first avail-
able sample with an ANC ≤500 cells/mm3, using rabbit red 
blood cells (RBC) [19]. All sera contained 10 mM ethylene gly-
col tetraacetic acid (EGTA) and 10  mM of Mg2+ (Mg/EGTA-
treated serum) to block the classic and lectin pathways and 
permit selective activation of the AP. Sera containing 10 mM 
ethylenediaminetetraacetic acid (EDTA) blocked all pathways 
and represented baseline hemolysis, and RBCs hemolyzed with 
sterile water represented 100% hemolysis. Serum concentra-
tions of 6.25%, 12.5%, and 25% were tested. Reaction mixtures 
were incubated for 60 minutes at 37°C. Samples were centri-
fuged and absorbance of the supernatants was measured at 
405 nm. Results are shown as the net absorbance, which was 
derived by subtracting baseline values (EDTA-treated serum) 
from absorbance obtained after lysis with Mg/EGTA-treated 
serum.
Statistical Analyses
Statistical analyses were conducted using either SAS version 
9.3 (SAS Institute, Inc., Cary, NC) or GraphPad Prism version 
7.0a. All graphs were produced with GraphPad Prism. Paired 
values were compared by Wilcoxon signed-rank test (GraphPad 
Prism).
RESULTS
Clinical Data on Subjects
Of the 27 patients included for analysis, the median age was 
54  years (range, 19–81  years) and 12 (44.4%) were males. 
Thirteen (48%) received autologous HSCT, 13 (48%) received 
allogeneic HSCT, and 1 (4%) received chemotherapy without 
HSCT. One of the 13 allogeneic HSCT was with umbilical cord 
blood. Temperature >38.0°C was registered among 14 patients 
(52%) at 1 or more time points during the study period. Four 
patients (15%) had positive blood cultures during the study.
The median number of blood samples obtained from each 
patient for the study was 4 (range, 3–6 samples). Twenty of 
the 27 patients (74.1%) had a blood sample obtained after the 
recovery of neutrophil counts. The median duration of the 
neutropenic period was 8 days (range, 3–25 days). The median 
length of stay in the hospital until receipt of chemotherapy for 
the 27 enrolled patients was 6 days (range, 0–7 days).
Properdin (P) Levels Were Significantly Lower During Neutropenia 
Compared With the Preneutropenic State, and P and Neutrophil Levels 
Declined Together After Neutropenia
Properdin levels obtained from neutropenic and baseline, non-
neutropenic serum samples are shown in Figure 1. Properdin 
levels in neutropenic samples (n = 61) were significantly lower 
than those from samples when neutrophil counts exceeded 
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500 cells/mm3 (n = 27) (median 6355 ng/mL vs 8392 ng/mL; 
P = 0.001, Mann-Whitney U test) (Figure 1A). This analysis 
did not include P levels obtained from samples after the recov-
ery of neutropenia.
Properdin levels were then analyzed in serum samples 
obtained over the course of neutropenia. Baseline samples 
were obtained from patients before neutropenia. The day of 
sample collection at the first occurrence of neutropenia was 
designated Day 0.  Subsequent samples were clustered into 
groups of several days, spanning Days 2–5 and Days 6–8. 
Seven subjects having neutropenia at Day 9 and beyond con-
stituted the third cluster. The mean ± standard error of the 
mean for each point or cluster is shown in Figure 1B. Mean 
baseline P levels were 9010 ± 647 ng/mL, which decreased 
to 7292 ± 616.1 ng/mL at the onset of neutropenia (Day 0). 
These data show that P levels trended down with neutrope-
nia. Comparisons between P levels obtained before neutro-
penia and either at the onset of neutropenia (Day 0) or at the 
last blood draw associated with neutropenia both showed a 
significant downward trend (Figure  2A and B, respectively; 
P < .0001 in each case).
Properdin Levels Do Not Increase With the Recovery of Neutrophil Counts
Properdin levels were measured in a subset of patients (n = 20) 
from whom samples were obtained after recovery of neutro-
phil counts (ANC >500 cells/mm3) to determine whether P 
levels increased with resolution of neutropenia. In contrast to 
the strong association between the decline in P concentration 
with the occurrence of neutropenia (Figure 2A and B), recovery 
of neutrophil counts was not associated with a rise in serum 
P concentrations; mean P levels associated with the last neu-
tropenic blood sample were 5428 ± 482.4  ng/mL compared 
with 5445 ± 553.6  ng/mL at time of neutrophil recovery 
(Figure 2C).
Effect of the Decline on Properdin Levels on Alternative Pathway 
Function
We next asked whether the decline in P levels associated with 
neutropenia negatively affected AP activity, as measured by 
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Figure 1. Comparison of properdin (P) levels collected during baseline (preneutropenic) and neutropenic states. (A) Samples collected from patients with neutropenia have 
significantly lower P levels than during the preneutropenic state (n = 27 for absolute neutrophil count [ANC] >500, n = 61 for ANC ≤500; P = .001; Mann-Whitney U test). 
(B) Correlation of P levels with neutropenia. Properdin levels are low during neutropenia compared with the baseline preneutropenic state. Plot shows the mean P levels, and 
error bars indicate ± standard error of the mean, with n indicating the number of patients included for each time cluster.
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Figure 2. Properdin (P) levels decline between pre-chemotherapy (baseline, obtained while absolute neutrophil count [ANC] >500) and neutropenia but remain low despite 
recovery of neutrophil count. (A) Comparison of P levels between baseline (ANC >500, closed circles) and initial neutropenic state (ANC ≤500, open circles) (n = 27 paired 
subject samples; P < .0001). (B) Comparison of P levels between baseline (ANC >500, closed circles) and final neutropenic state (ANC ≤500, open triangles) (n = 27 paired 
subject samples; P < .0001). (C) Comparison of P levels between the final neutropenic state (ANC ≤500, open triangles) and recovery of ANC >500 (closed triangles) from 
the subset of patients whose recovery samples were available (n = 20 paired subject samples; P value not significant; Wilcoxon matched-pairs signed-rank test).
4 • OFID • Tsyrkunou et al
lysis of rabbit RBCs by Mg/EGTA-treated serum. Hemolytic 
assays were performed using serum concentrations of 6.25%, 
12.5%, and 25%. There was no correlation between the ANC 
and AP hemolytic activity of serum noted at the 2 higher 
concentrations of serum tested (data not shown). A  small 
albeit statistically significant decline in AP activity with 
6.25% serum was observed with the onset of neutropenia 
(Figure 3). 
DISCUSSION
The main finding in this study was that chemotherapy-in-
duced neutropenia is associated with a decline in serum P 
levels and a modest decrease in AP hemolytic activity at 
low serum concentrations. At baseline, patients were noted 
to have P levels within the typical reference range [13–15]. 
The onset of neutropenia was accompanied by a decline in 
mean P levels by ~19%. The mean P levels in subjects who 
remained neutropenic for an additional 2 to 5 days dropped 
further to ~32% of the baseline mean P levels, highlighting 
the importance of neutrophils in contributing to serum P 
levels [6]. However, P levels did not appear to drop further 
in persons with more prolonged neutropenia, suggesting 
that cells other than neutrophils contribute significantly to P 
synthesis. Indeed, T cells and monocytes/macrophages also 
synthesize P [9–11, 20] and could contribute to the pool of 
circulating P in the absence of neutrophils. An alternative 
explanation is that the half-life for P is long. However, the 
relatively rapid decline in P levels with neutropenia sug-
gests a relatively short half-life of free P in serum, consistent 
with the rapid turnover of other complement proteins [21]. 
Another possible, and not mutually exclusive, explanation 
for low P levels is increased consumption of P secondary to 
binding to apoptotic cells or debris [22, 23] that may be gen-
erated during chemotherapy.
Patients receiving aggressive chemotherapy are at increased 
risk for systemic infections [18]. Patients with severe neutrope-
nia are at risk for infection caused by both Gram-positive and 
Gram-negative bacteria [17, 24]. The positive feedback loop of 
the AP of complement serves to effectively amplify C3 depo-
sition on microbes that is often initiated by the classic and/or 
lectin pathways. In some instances, P can act as a pattern recog-
nition molecule, binding to the surface of select Gram-negative 
bacteria and activating the complement system [25]. Our data 
indicate that the hemolytic activity of the AP during neutrope-
nia was relatively well preserved despite the modest drop in P 
levels. A slight compromise in AP activity was noted at the onset 
of neutropenia and only at low (6.25%) serum concentrations, 
which was expected because the activity of the AP is highly con-
centration-dependent [26]. Thus, the effects of lower P levels 
and the resulting decrease in C3 convertase stability are likely to 
be manifest at lower serum concentrations. Uchiyama et al [20] 
recently reported that individuals receiving interferon (IFN)-α 
treatment for hepatitis C had increased P levels compared with 
pre- or posttreatment levels. They demonstrated that treating 
monocytes and neutrophils with IFN-α resulted in increased P 
release from these cells in culture. Blocking P function in the 
plasma of IFN-α-treated individuals decreased the ability of 
monocytes to kill group A streptococci, which underscores the 
role of P in cell-mediated innate immune defenses.
Of note, the recovery of neutrophil counts was not associ-
ated with an increase in P levels. A  possible explanation is 
inadequate P synthesis by the newly formed neutrophils. The 
lack of longer-term follow-up to determine the fate of P levels 
after neutrophil recovery is a limitation of our study. However, 
most subjects were discharged immediately upon recovery of 
neutrophils, which precluded obtaining further serum samples 
for P level determination. Recent data have underscored the 
importance of P in binding to neutrophils and promoting AP 
activation on the cell surface, which in turn enhanced neutro-
phil function by increasing CD11b expression and the oxidative 
burst [27]. Properdin plays a crucial role in the formation of 
platelet-granulocyte aggregates [28], which are believed to play 
a key role in fighting infections. Thus, in the face of lower P 
levels, it is possible that the newly formed neutrophils may not 
function optimally to ward off infections.
CONCLUSIONS
In conclusion, our data show that chemotherapy-induced neu-
tropenia results in a significant decline in P levels, which does 
not normalize immediately at the time of recovery of neutro-
phils. Despite the drop in P serum levels, the hemolytic function 
of the AP is only slightly compromised at low serum concen-
trations. Whether lower P levels during neutropenia contribute 
directly to the increased risk of infections in this patient popu-
lation merits further study.
 Acknowledgments
We thank all the staff of the inpatient bone marrow unit at the 
University of Massachusetts Medical Center, without whom this study 
1.5
1.0
0.5
0.0
Baseline
P = .02
A
P 
ac
tiv
ity
, 6
.2
5%
 s
er
um
(O
D
40
5n
m
)
Initial ANC ≤500
Figure 3. Alternative pathway (AP) activity declines between baseline (preneu-
tropenic) and the initial neutropenic state. Serum concentrations of 6.25% were 
tested (n = 27 paired subject samples; P = .02; Wilcoxon matched-pairs signed-rank 
test).
Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia • OFID • 5
would not be possible. We also thank Melanie Trombly, University of 
Massachusetts Medical School, for assistance with preparation of the 
manuscript.
Author contributions. A.  T., B.  K., and S.  A.  performed the experi-
ments. A. T., B. K., R. W. F., R. N., S. M. L., J. P. W., and S. R. designed the 
study. A. T., J. P. W., and S. R. wrote the paper. B. B. performed statistical 
analysis. 
Potential conflicts of interest. All authors: No reported conflicts.
The author has submitted the ICMJE Form for Potential Conflicts of 
Interest. Conflicts that the editors consider relevant to the content of the 
manuscript have been disclosed.
References
1. Botto M. C3. In: Morley BJ, Walport MJ, eds. The Complement Facts Book. 
London: Academic Press; 2000: pp 88–94.
2. Schreiber RD, Pangburn MK, Lesavre PH, Müller-Eberhard HJ. Initiation of the 
alternative pathway of complement: recognition of activators by bound C3b and 
assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S 
A 1978; 75:3948–52.
3. Pangburn MK, Müller-Eberhard HJ. Initiation of the alternative complement 
pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci 
1983; 421:291–8.
4. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate com-
plement activation by binding specific target surfaces and providing a platform 
for de novo convertase assembly. J Immunol 2007; 179:2600–8.
5. Pillemer L, Blum L, Lepow IH, et  al. The properdin system and immunity. 
I. Demonstration and isolation of a new serum protein, properdin, and its role in 
immune phenomena. Science 1954; 120:279–85.
6. Wirthmueller U, Dewald B, Thelen M, et  al. Properdin, a positive regulator of 
complement activation, is released from secondary granules of stimulated periph-
eral blood neutrophils. J Immunol 1997; 158:4444–51.
7. Whaley K. Biosynthesis of the complement components and the regulatory pro-
teins of the alternative complement pathway by human peripheral blood mono-
cytes. J Exp Med 1980; 151:501–16.
8. Minta JO. Biosynthesis of complement factor P (properdin) by the human 
pre-monocyte cell line (U-937). Mol Immunol 1988; 25:1363–70.
9. Schwaeble W, Dippold WG, Schäfer MK, et al. Properdin, a positive regulator of 
complement activation, is expressed in human T cell lines and peripheral blood T 
cells. J Immunol 1993; 151:2521–8.
10. Schwaeble W, Huemer HP, Möst J, et al. Expression of properdin in human mono-
cytes. Eur J Biochem 1994; 219:759–64.
11. Farries TC, Atkinson JP. Biosynthesis of properdin. J Immunol 1989; 142:842–7.
12. Bongrazio M, Pries AR, Zakrzewicz A. The endothelium as physiological source 
of properdin: role of wall shear stress. Mol Immunol 2003; 39:669–75.
13. Fijen CA, van den Bogaard R, Schipper M, et al. Properdin deficiency: molecular 
basis and disease association. Mol Immunol 1999; 36:863–7.
14. Pangburn MK. Analysis of the natural polymeric forms of human properdin and 
their functions in complement activation. J Immunol 1989; 142:202–7.
15. Nolan KF, Reid KB. Properdin. Methods Enzymol 1993; 223:35–46.
16. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058–66.
17. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between 
circulating leukocytes and infection in patients with acute leukemia. Ann Intern 
Med 1966; 64:328–40.
18. Stover CM, McDonald J, Byrne S, et al. Properdin levels in human sepsis. Front 
Immunol 2015; 6:24.
19. Morgan BP. Complement Methods and Protocols. Humana Press; 2000:61–71.
20. Uchiyama S, Keller N, Schlaepfer E, et  al. Interferon α-enhanced clearance of 
group A Streptococcus despite neutropenia. J Infect Dis 2016; 214:321–8.
21. Ruddy S, Carpenter CB, Chin KW, et  al. Human complement metabolism: an 
analysis of 144 studies 1. Medicine 1975; 54:165–178.
22. Xu W, Berger SP, Trouw LA, et al. Properdin binds to late apoptotic and necrotic 
cells independently of C3b and regulates alternative pathway complement activa-
tion. J Immunol 2008; 180:7613–21.
23. Kemper C, Mitchell LM, Zhang L, Hourcade DE. The complement protein prop-
erdin binds apoptotic T cells and promotes complement activation and phagocy-
tosis. Proc Natl Acad Sci U S A 2008; 105:9023–8.
24. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients 
and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004; 
39(Suppl 1):S25–31.
25. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pat-
tern-recognition molecule. Annu Rev Immunol 2010; 28:131–55.
26. Schreiber RD, Morrison DC, Podack ER, Müller-Eberhard HJ. Bactericidal activ-
ity of the alternative complement pathway generated from 11 isolated plasma pro-
teins. J Exp Med 1979; 149:870–82.
27. Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a 
positive feedback amplification of neutrophil activation. Blood 2011; 117:1340–9.
28. Blatt AZ, Saggu G, Kulkarni KV, et  al. Properdin-mediated C5a production 
enhances stable binding of platelets to granulocytes in human whole blood. J 
Immunol 2016; 196:4671–80.
